Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Scancell
Biotech
Scancell heads to Nasdaq via reverse merger with Neuphoria
Scancell and Neuphoria have agreed to a reverse merger that will result in a Nasdaq listing for Scancell and a resolution for Neuphoria’s shareholders.
Will Maddox
Jul 23, 2026 10:13am
Scancell bids for Nasdaq-listed Neuphoria to raise US profile
Jun 29, 2026 7:55am
Scancell picks winner from phase 2 cancer vaccine face-off
Jul 22, 2025 9:38am
Genmab buys 2nd antibody from Scancell in deal worth up to $630M
Dec 4, 2024 11:55am
Scancell enjoys stock bounce on back of cancer vaccine data
Sep 19, 2023 10:55am
Immunocore lifer leaves to head research at TCR rival Scancell
Jan 21, 2019 7:59am